Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA Grants Priority Review of INVOKANA® sNDA for Chronic Kidney Disease in Patients with Type 2 Diabetes

americanpharmaceuticalreviewMay 24, 2019

Tag: FDA , INVOKANA® sNDA , type 2 diabetes

PharmaSources Customer Service